Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance

Cancers

Yi-Jun Wang¹  Yun-Kai Zhang¹  Rishil J. Kathawala¹ 

[1] Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA;

关键词: multidrug resistance;    ABC transporters;    tyrosine kinase inhibitor;    clinical relevance;    pharmacogenomics;   

DOI  :  10.3390/cancers6041925

来源: mdpi

【 摘 要 】

The phenomenon of multidrug resistance (MDR) has attenuated the efficacy of anticancer drugs and the possibility of successful cancer chemotherapy. ATP-binding cassette (ABC) transporters play an essential role in mediating MDR in cancer cells by increasing efflux of drugs from cancer cells, hence reducing the intracellular accumulation of chemotherapeutic drugs. Interestingly, small-molecule tyrosine kinase inhibitors (TKIs), such as AST1306, lapatinib, linsitinib, masitinib, motesanib, nilotinib, telatinib and WHI-P154, have been found to have the capability to overcome anticancer drug resistance by inhibiting ABC transporters in recent years. This review will focus on some of the latest and clinical developments with ABC transporters, TKIs and anticancer drug resistance.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.